To the Editor.—In a recent article published in the January issue of the Archives, Clayman et al1 described the possible correlation among serum levels of acute-phase proteins and in vitro serum modulation of the lymphokine-activated killer cell induction phase and in vivo interleukin 2 (IL-2)-induced toxicity in patients with head and neck cancer who are receiving IL-2/interferon alfa immunotherapy. The authors, in agreement with others,2 found elevated levels of such proteins in head and neck cancer patients before therapy was started and suggested the central role of IL-1 in the control of their production and its modulation by the recombinant cytokines used for therapy. In this article, however, the possible role of IL-6 in controlling liver production of acute-phase protein levels in the serum has not been taken into account. Interleukin 6 is a multifunctional cytokine with pleiotropic action that regulates the acute-phase response of the organism
GALLO O, GORI AM, ATTANASIO M, et al. Acute-Phase Proteins and Interleukin 6 Serum Level in Head and Neck Cancer. Arch Otolaryngol Head Neck Surg. 1992;118(12):1366. doi:10.1001/archotol.1992.01880120092019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: